Prevention of severe cutaneous adverse drug reactions: The emerging value of pharmacogenetic screening

CMAJ. Canadian Medical Association Journal

Volumn 182, Issue 5, 2010, Pages 476-480

  Fernando, Suran L ^a,b   Broadfoot, Andrew J ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ALLOPURINOL; AMINOPENICILLIN; CARBAMAZEPINE; CORTICOSTEROID; CYCLOSPORIN; DAPSONE; HLA B ANTIGEN; IMMUNOGLOBULIN; LAMOTRIGINE; LUBRICATING AGENT; MELOXICAM; MEXILETINE; MINOCYCLINE; NEVIRAPINE; PHENOBARBITAL; PHENYTOIN; PIROXICAM; RETINOL; SALAZOSULFAPYRIDINE; SULFONAMIDE; TENOXICAM; ZONISAMIDE; ANTICONVULSIVE AGENT; ANTIGOUT AGENT; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTICLE; CASE REPORT; CHINESE; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; DRY EYE; EMERGENCY WARD; FEVER; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; HUMAN; KERATOCONJUNCTIVITIS; LYMPHOCYTIC INFILTRATION; MACULOPAPULAR RASH; MALE; MOUTH PAIN; MOUTH ULCER; PATHOGENESIS; PHARMACOGENETICS; PHYSICAL EXAMINATION; RASH; SKIN BIOPSY; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; URETHRITIS; VISUAL IMPAIRMENT; ALLELE; ASIAN; CHEMICALLY INDUCED DISORDER; CHINA; GENETIC PREDISPOSITION; GENETICS; PASSIVE IMMUNIZATION;

ADULT; ALLELES; ALLOPURINOL; ANTICONVULSANTS; ASIAN CONTINENTAL ANCESTRY GROUP; CARBAMAZEPINE; CHINA; CYCLOSPORINE; DRUG HYPERSENSITIVITY; EPIDERMAL NECROLYSIS, TOXIC; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; GOUT SUPPRESSANTS; HLA-B ANTIGENS; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOSUPPRESSIVE AGENTS; KERATOCONJUNCTIVITIS; MALE; STEVENS-JOHNSON SYNDROME; URETHRITIS;

EID: 77950878238     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.090401     Document Type: Article

References (26)

1. Hung SI, Chung WH, Liou LB, et al. HLA-B*5801 as a genetic marker for severe cutaneous reactions caused by allopurinol. Proc Natl Acad Sci U S A 2005;102:4134-4139
2. Khalili B, Bahna SL. Pathogenesis and recent therapeutic trends in Stevens-Johnson syndrome and toxic epidermal necrolysis. Ann Allergy Asthma Immunol 2006;97:272-280
3. Paul C, Wolkenstein P, Adle H, et al. Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis. Br J Dermatol 1996;134:710-714 (Pubitemid 26120740)
4. Guillaume JC, Roujeau JC, Revuz J, et al. The culprit drugs in 87 cases of toxic epidermal necrolysis (Lyell's syndrome). Arch Dermatol 1987;123:1166-1170 (Pubitemid 17129796)
5. Rzany B, Mockenhaupt M, Baur S, et al. Epidemiology of erythema exsudativum multiforme majot (EEMM), Stevens-Johsnon syndrome (SJS) and toxic epidermal necrolysis (TEN) in Germany (1990-1992). Structure and results of a population based study. J Clin Epidemiol 1996;49:769-773
6. Mockenhaupt M, Norgauer J. Cutaneous adverse drug reactions: Stevens-Johnson syndrome and toxic epidermal necrolysis. Allergy Clin Immunol Int 2002;14:143-150 (Pubitemid 34753025)
7. Shiohara T, Kano Y. A complex interaction between drug allergy and viral infection. Clin Rev Allergy Immunol 2007;33:124-133 (Pubitemid 351514149)
8. Roujeau J-C, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995;333:1600-1608
9. Hung S-I, Chung W-H, Chen Y-T. HLA-B genotyping to detect carbamazepine induced Stevens-Johnson syndrome: implications for personalizing medicine. Personalized Med 2005;2:225-237
10. Hung SI, Chung WH, Chen YT. Genetics of severe drug hypersensitivity reactions in Han Chinese. In: Pichler WJ, editor. Drug hypersensitivity. Basel (Switzerland): Karger; 2007. p. 105-114
11. Chung WH, Hung SI, Hong HS, et al. Medical genetics: a marker for Stevens- Johnson syndrome. Nature 2004;428:486.
12. Hung SI, Chung WH, Jee SH, et al. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet Genomics 2006; 16: 297-306.
13. Lonjou C, Thomas L, Borot N, et al.; RegiSCAR Group. A marker for Stevens- Johnson syndrome ...: ethnicity matters. Pharmacogenomics J 2006;6:265-268
14. Daar AS, Singer PA. Pharmacogenetics and geographical ancestry: implications for drug development and global health. Nat Rev Genet 2005;6:241-246
15. Ueta M, Sotozono C, Inatomi T, et al. Association of Fas Ligand gene polymorphism with Stevens-Johnson syndrome. Br J Ophthalmol 2008;92:989-991 (Pubitemid 351969685)
16. Ueta M, Sotozono C, Inatomi T, et al. Toll-like receptor 3 gene polymorphisms in Japanese patients with Stevens-Johnson syndrome. Br J Ophthalmol 2007;91:962-965 (Pubitemid 47013114)
17. Ueta M, Sotozono C, Inatomi T, et al. Association of combined IL-13/IL-4R signaling pathway gene polymorphism with Stevens-Johnson syndrome accompanied by ocular surface complications. Invest Ophthalmol Vis Sci 2008;49:1809-1813
18. Black box warnings. Black Box Information Center; 2009. Available: http://formularyproductions. com/blackbox/ (accessed 2009 Sept. 21).
19. New safety information for the anti-epileptic drug TEGRETOL (carbamazepine). Ottawa (ON): Health Canada; 2008. Available: www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/-2008/tegretol-hpc-cps-eng. php (accessed 2009 June 30).
20. Rauch A, Nolan D, Martin A, et al. Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study. Clin Infect Dis 2006;43:99-102.
21. Kaniwa N, Saito Y, Aihara M, et al.; JSAR Research Group. HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics 2008;9:1617-1622
22. Lonjou C, Borot N, Sekula P, et al.; RegiSCAR Group. A European study of HLAB in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics 2008;18:99-107.
23. Vázquez-Mellado J, Morales EM, Pacheco-Tena C, et al. Relation between adverse events associated with allopurinol and renal function in patients with gout. Ann Rheum Dis 2001;60:981-983
24. Posadas SJ, Padial A, Torres MJ, et al. Delayed reactions to drugs show levels of perforin, granzyme B, and Fas-L to be related to disease severity. J Allergy Clin Immunol 2002;109:155-161
25. Stur K, Karlhofer FM, Stingl G. Soluble FAS ligand: a discriminating feature between drug-induced skin eruptions and viral exanthemas. J Invest Dermatol 2007;127:802-807 (Pubitemid 46434660)
26. Chung WH, Hung SI, Yang JY, et al. T. Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nat Med 2008;14:1343-1350